pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: mRNA

Sep 22, 2023

PHYLEX BIOSCIENCES ANNOUNCES NIPAH VIRUS VACCINE INITIATIVE WITH ITS NANOPARTICLE mRNA VACCINE TECHNOLOGY

Jul 25, 2023

Combined Therapeutics to Present Multi-Organ Protection (MOP) mRNA Vaccine Platform at the 3rd mRNA-Based Therapeutics Summit

May 2, 2023

Nutcracker Therapeutics Presenting on Nutshell™ mRNA Delivery Technology at the 2023 Oligonucleotide and Peptide Therapeutics Conference

Apr 26, 2023

Anima Biotech's Webinar Series: Exploring the Potential of mRNA Biology for Drug Discovery and Therapeutic Intervention

Apr 19, 2023

Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting

Apr 17, 2023

Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023

Mar 29, 2023

Synthetic mRNA Market for Cancer Treatment size to grow at a CAGR of 13.4% by 2029: Growth opportunities led by BioNTech SE, Moderna Inc., CureVac AG, eTheRNA immunotherapies NV - Brandessence Market Research

Mar 13, 2023

Combined Therapeutics Granted Patent for its mRNA Vaccine Platform by USPTO

Feb 28, 2023

Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia

Feb 6, 2023

RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting

Jan 10, 2023

ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy

Jan 10, 2023

CF Foundation Invests Up to $15M in ReCode Therapeutics for Development of mRNA Therapy

Nov 28, 2022

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

Nov 11, 2022

Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022

Nov 10, 2022

Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Sep 14, 2022

Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering

Aug 23, 2022

mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA

Jul 7, 2022

Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology

Jun 29, 2022

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

Jun 8, 2022

Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting

May 18, 2022

ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference

May 15, 2022

ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference

May 11, 2022

Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans

Apr 10, 2022

Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming

Apr 10, 2022

Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming

Mar 31, 2022

Tevard Biosciences licenses mRNA Amplifier technology from Johns Hopkins University

Mar 29, 2022

RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines

Mar 23, 2022

PHYLEX BIOSCIENCES PUBLISHES POSITIVE RESULTS OF PROTECTION STUDY AGAINST SARS-CoV-2 DELTA VARIANT WITH ITS SECOND-GENERATION mRNA VACCINE

Mar 21, 2022

RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics

Mar 14, 2022

Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform

Mar 9, 2022

Myeloid Therapeutics Announces Late-Breaking Presentations on mRNA in-vivo Delivery and ATAK™ CAR Receptors at AACR 2022 Annual Meeting

Feb 14, 2022

Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2

Feb 8, 2022

Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission

Feb 3, 2022

eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to access mRNA technologies

Nov 22, 2021

Codex DNA and RNAimmune Announce Collaboration to Optimize Development of Future mRNA Synthesis and Delivery Kits

Nov 9, 2021

Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference

Nov 3, 2021

ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis Program at 2021 North American Cystic Fibrosis Conference

Nov 2, 2021

Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics

Oct 21, 2021

ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

Sep 29, 2021

Recbio and Rhegen Signed an mRNA Vaccine Cooperation Agreement

Aug 10, 2021

Aldevron's Collaboration with Ginkgo Bioworks Yields Manufacturing Breakthrough for Vaccinia Capping Enzyme Used for Manufacturing of mRNA Vaccines

Aug 5, 2021

ReCode Therapeutics Presents Encouraging Preclinical Data from Inhaled mRNA Therapeutics Program in Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference

Aug 4, 2021

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer

Jul 13, 2021

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement USA - English USA - English

Jun 23, 2021

Strand Therapeutics Raises $52M in Oversubscribed Series A Round

Jun 23, 2021

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix

Jun 11, 2021

ReCode Therapeutics Presents Preclinical Data Using SORT-LNP™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)

Mar 22, 2021

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

Mar 18, 2021

Anima Biotech Announces Strategic Collaboration with Takeda to Discover and Develop mRNA Translation Modulators for Neurological Diseases

Mar 4, 2021

ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases

Feb 3, 2021

Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technology

Jan 11, 2021

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

Nov 17, 2020

Factor Bioscience Successfully Defends mRNA Gene Editing Patent USA - English Россия - English Россия - Pусский

Nov 10, 2020

Factor Bioscience Granted Second U.S. Patent for mRNA Vectorization of TALENs Technology

Sep 23, 2020

Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform

Aug 24, 2020

RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines

Jun 16, 2020

eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept

Jun 11, 2020

Sirnaomics Announces Decision to Spin off RNAimmune to Develop Novel mRNA Therapeutics and Vaccines

May 26, 2020

Factor Bioscience Granted U.S. Patent for mRNA Vectorization of TALENs Technology

Mar 26, 2020

Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration

Mar 24, 2020

eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations

Jun 4, 2019

Strand Therapeutics Announces $6 Million Seed Financing to Advance its Programmable mRNA Therapeutics Platform

May 16, 2019

CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies

Feb 27, 2019

CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases

Jan 8, 2019

CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV

Oct 23, 2018

CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA Rabies Vaccine

Oct 8, 2018

eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies

Jun 26, 2018

Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk's STAR* Technology Platform

Jun 26, 2018

Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk's STAR* Technology Platform USA - English USA - Français USA - Deutsch USA - español

Jun 11, 2018

Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccines for Infectious Diseases using Novel mRNA Technology

May 12, 2018

Translate Bio Announces FDA Clearance to Proceed with Phase 1/2 Clinical Trial in Patients with Cystic Fibrosis (CF)

Feb 13, 2018

CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria

Jan 10, 2018

CureVac Highlights Key 2018 Corporate Milestones and Outlook

Jan 4, 2018

CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

Nov 13, 2017

CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

Oct 23, 2017

Publication in npj Vaccines Demonstrates CureVac's RNActive Vaccine is Superior to Licensed Vaccines

Oct 18, 2017

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Sep 25, 2017

eTheRNA immunotherapies Awarded €1 Million Grant From Flanders Innovation and Entrepreneurship to Further Upgrade its State-of-the-art Production Process for TriMix mRNA Immunotherapies

Aug 15, 2017

Publication in EMBO Molecular Medicine Demonstrates CureVac's Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

Jul 26, 2017

CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

Jul 20, 2017

CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies

Jun 30, 2017

eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy into First Oncology Clinical Studies

Jun 13, 2017

CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines

Nov 8, 2016

CureVac Receives Broad Patent for RNAntibody Technology

Mar 21, 2016

CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion

Feb 18, 2016

CureVac announces "MERAN" has been approved by the World Health Organization as suffix for mRNA drug substances

Nov 3, 2015

CureVac raises $110 Million in a private placement

Sep 10, 2015

IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates

Jul 7, 2015

CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer

Jun 24, 2015

CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs